治疗外阴阴道念珠菌病的葡聚糖合成酶抑制剂ibrexafungerp

Glucan synthase inhibitor ibrexafungerp in treatment of vulvovaginal candidiasis

ibrexafungerp是新型的高生物利用度的口服葡聚糖合成酶抑制剂,与目前临床上使用的棘白菌素类抗真菌药物相比,具有更强的抗真菌活性和更好的药动学特性。ibrexafungerp对耐氟康唑的念珠菌和曲霉菌有良好的抵抗力。临床试验证实其能有效治疗外阴阴道念珠菌病,并具有良好的安全性和耐受性,最常见的不良事件是腹泻、恶心和腹痛。

Ibrexafungerp is a new type of highly bioavailable oral glucan synthase inhibitor. Compared with the antifungal drugs of echinocandins that have been used clinically, ibrexafungerp has stronger antifungal activity and better pharmacokinetic properties. It demonstrates good resistance to fluconazole-resistant strains of Candida and Aspergillus. Clinical trials have confirmed its efficacy in treating vulvovaginal candidiasis with good safety and tolerance. The most common adverse events are diarrhea, nausea and abdominal pain.